| The incidence and severity of adverse events affecting patients after discharge from the hospital AJ Forster, HJ Murff, JF Peterson, TK Gandhi, DW Bates Annals of internal medicine 138 (3), 161-167, 2003 | 2424 | 2003 |
| Adverse drug events in ambulatory care TK Gandhi, SN Weingart, J Borus, AC Seger, J Peterson, E Burdick, ... New England journal of medicine 348 (16), 1556-1564, 2003 | 1903 | 2003 |
| Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. P Pandharipande, A Shintani, J Peterson, BT Pun, GR Wilkinson, ... Anesthesiology 104 (1), 21-26, 2006 | 1538 | 2006 |
| Delirium and its motoric subtypes: a study of 614 critically ill patients JF Peterson, BT Pun, RS Dittus, JWW Thomason, JC Jackson, ... Journal of the American Geriatrics Society 54 (3), 479-484, 2006 | 944 | 2006 |
| Intensive care unit delirium is an independent predictor of longer hospital stay: a prospective analysis of 261 non-ventilated patients JWW Thomason, A Shintani, JF Peterson, BT Pun, JC Jackson, EW Ely Critical care 9, 1-7, 2005 | 780 | 2005 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ... Clinical Pharmacology & Therapeutics 98 (1), 19-24, 2015 | 756 | 2015 |
| Adverse drug events occurring following hospital discharge AJ Forster, HJ Murff, JF Peterson, TK Gandhi, DW Bates Journal of general internal medicine 20, 317-323, 2005 | 648 | 2005 |
| Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) KE Caudle, HM Dunnenberger, RR Freimuth, JF Peterson, JD Burlison, ... Genetics in Medicine 19 (2), 215-223, 2017 | 539 | 2017 |
| Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project JM Pulley, JC Denny, JF Peterson, GR Bernard, CL Vnencak‐Jones, ... Clinical Pharmacology & Therapeutics 92 (1), 87-95, 2012 | 438 | 2012 |
| Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing SL Van Driest, Y Shi, EA Bowton, JS Schildcrout, JF Peterson, J Pulley, ... Clinical Pharmacology & Therapeutics 95 (4), 423-431, 2014 | 361 | 2014 |
| Large-scale implementation of sedation and delirium monitoring in the intensive care unit: a report from two medical centers BT Pun, SM Gordon, JF Peterson, AK Shintani, JC Jackson, J Foss, ... Critical care medicine 33 (6), 1199-1205, 2005 | 350 | 2005 |
| Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention LH Cavallari, CR Lee, AL Beitelshees, RM Cooper-DeHoff, JD Duarte, ... JACC: Cardiovascular Interventions 11 (2), 181-191, 2018 | 293 | 2018 |
| Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury ED Siew, ME Matheny, TA Ikizler, JB Lewis, RA Miller, LR Waitman, ... Kidney international 77 (6), 536-542, 2010 | 293 | 2010 |
| Estimating baseline kidney function in hospitalized patients with impaired kidney function ED Siew, TA Ikizler, ME Matheny, Y Shi, JS Schildcrout, I Danciu, ... Clinical journal of the American society of nephrology 7 (5), 712-719, 2012 | 290 | 2012 |
| Design and anticipated outcomes of the eMERGE‐PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems LJ Rasmussen‐Torvik, SC Stallings, AS Gordon, B Almoguera, ... Clinical Pharmacology & Therapeutics 96 (4), 482-489, 2014 | 278 | 2014 |
| The design and evaluation of prototype eco-feedback displays for fixture-level water usage data J Froehlich, L Findlater, M Ostergren, S Ramanathan, J Peterson, I Wragg, ... Proceedings of the SIGCHI conference on human factors in computing systems …, 2012 | 227 | 2012 |
| Outpatient nephrology referral rates after acute kidney injury ED Siew, JF Peterson, SK Eden, AM Hung, T Speroff, TA Ikizler, ... Journal of the American Society of Nephrology 23 (2), 305-312, 2012 | 225 | 2012 |
| Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping JS Schildcrout, JC Denny, E Bowton, W Gregg, JM Pulley, MA Basford, ... Clinical Pharmacology & Therapeutics 92 (2), 235-242, 2012 | 213 | 2012 |
| Linking laboratory and pharmacy: opportunities for reducing errors and improving care GD Schiff, D Klass, J Peterson, G Shah, DW Bates Archives of internal medicine 163 (8), 893-900, 2003 | 210 | 2003 |
| The pharmacogenomics research network translational pharmacogenetics program: overcoming challenges of real‐world implementation AR Shuldiner, MV Relling, JF Peterson, K Hicks, RR Freimuth, W Sadee, ... Clinical Pharmacology & Therapeutics 94 (2), 207-210, 2013 | 208 | 2013 |
David BatesProfessor of Medicine, Harvard Medical SchoolVerified email at partners.org
